Patents by Inventor Sudhir Kumar Sharma
Sudhir Kumar Sharma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11532352Abstract: This disclosure describes a memory cell array with enhanced read sensing margin. The memory cell array includes a write port and a read port being connected through first and second data storage lines. The memory cell array further includes multiple word lines and bit lines arranged in rows and columns such that the read port is coupled to a read word line, a read bit line, and a virtual ground. The read port includes a first transistor coupled to at least the read bit line and the virtual ground, a second transistor coupled to at least the first data storage line and the first transistor, a third transistor coupled to at least the second data storage line and the read word line, and a fourth transistor coupled at least the first data storage line and the read word line.Type: GrantFiled: September 18, 2020Date of Patent: December 20, 2022Assignee: SYNOPSYS, INC.Inventors: M. Sultan M. Siddiqui, Sudhir Kumar Sharma, Sudhir Kumar, Ravindra Kumar Shrivastava
-
Patent number: 11062766Abstract: A structure for an integrated circuit is disclosed for storing data. The integrated circuit includes a memory cell array of bit cells configured in a static random access memory (SRAM) architecture. The memory cell array is coupled to wordlines arranged in rows that control operations such as Read and Write operations. To enhance the read sensing margin of the SRAM configuration, the read port of a bit cell may include a wordline that drives two transistors (e.g., a PMOS and an NMOS transistor) to reduce data-dependent current leakage from a read bitline. An additional weak transistor keeper configuration may be used in the integrated circuit to compensate for current leakage from the read bitline. For example, a weak NMOS keeper that includes a sense amplifier, an inverter, and an NMOS connected to supply voltage VDD provides a path between the read bitline and VDD through the weak NMOS keeper.Type: GrantFiled: January 3, 2020Date of Patent: July 13, 2021Assignee: Synopsys, Inc.Inventors: M. Sultan M. Siddiqui, Sudhir Kumar Sharma, Saurabh Porwal, Khatik Bhagvan Pannalal, Sudhir Kumar
-
Publication number: 20210090639Abstract: This disclosure describes a memory cell array with enhanced read sensing margin. The memory cell array includes a write port and a read port being connected through first and second data storage lines. The memory cell array further includes multiple word lines and bit lines arranged in rows and columns such that the read port is coupled to a read word line, a read bit line, and a virtual ground. The read port includes a first transistor coupled to at least the read bit line and the virtual ground, a second transistor coupled to at least the first data storage line and the first transistor, a third transistor coupled to at least the second data storage line and the read word line, and a fourth transistor coupled at least the first data storage line and the read word line.Type: ApplicationFiled: September 18, 2020Publication date: March 25, 2021Applicant: Synopsys, Inc.Inventors: M. Sultan M. SIDDIQUI, Sudhir Kumar SHARMA, Sudhir KUMAR, Ravindra Kumar SHRIVASTAVA
-
Publication number: 20200219558Abstract: A structure for an integrated circuit is disclosed for storing data. The integrated circuit includes a memory cell array of bit cells configured in a static random access memory (SRAM) architecture. The memory cell array is coupled to wordlines arranged in rows that control operations such as Read and Write operations. To enhance the read sensing margin of the SRAM configuration, the read port of a bit cell may include a wordline that drives two transistors (e.g., a PMOS and an NMOS transistor) to reduce data-dependent current leakage from a read bitline. An additional weak transistor keeper configuration may be used in the integrated circuit to compensate for current leakage from the read bitline. For example, a weak NMOS keeper that includes a sense amplifier, an inverter, and an NMOS connected to supply voltage VDD provides a path between the read bitline and VDD through the weak NMOS keeper.Type: ApplicationFiled: January 3, 2020Publication date: July 9, 2020Inventors: M. Sultan M. Siddiqui, Sudhir Kumar Sharma, Saurabh Porwal, Khatik Bhagvan Pannalal, Sudhir Kumar
-
Patent number: 9133116Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).Type: GrantFiled: September 27, 2011Date of Patent: September 15, 2015Assignee: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Nishan Singh, Sudhir Kumar Sharma
-
Patent number: 9018249Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).Type: GrantFiled: September 12, 2012Date of Patent: April 28, 2015Assignee: Panacea Biotec LimitedInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S. Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
-
Publication number: 20140378540Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).Type: ApplicationFiled: September 12, 2012Publication date: December 25, 2014Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
-
Patent number: 8906913Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.Type: GrantFiled: June 22, 2010Date of Patent: December 9, 2014Assignee: Panacea Biotec LimitedInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur, Sandeep Kanwar, Nishan Singh, Gurmeet Kaur Nanda, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Patent number: 8841306Abstract: The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H.Type: GrantFiled: November 18, 2009Date of Patent: September 23, 2014Assignee: Panacea Biotec Ltd.Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Sandeep Kanwar, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Publication number: 20140228303Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).Type: ApplicationFiled: June 13, 2012Publication date: August 14, 2014Applicant: Panacea Biotec LtdInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
-
Publication number: 20130253029Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).Type: ApplicationFiled: September 27, 2011Publication date: September 26, 2013Applicant: Panacea Biotec LtdInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Nishan Singh, Sudhir Kumar Sharma
-
Patent number: 8455479Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).Type: GrantFiled: January 23, 2009Date of Patent: June 4, 2013Assignee: Panacea Biotec LimitedInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Nishan Singh, Gurmeet Kaur Nanda, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Publication number: 20120165320Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.Type: ApplicationFiled: June 22, 2010Publication date: June 28, 2012Applicant: PANACEA BIOTEC LTD.Inventors: Rajseh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur, Sandeep Kanwar, Nishan Singh, Gurmeet Kaur Nanda, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Publication number: 20110245258Abstract: The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H.Type: ApplicationFiled: November 18, 2009Publication date: October 6, 2011Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Sandeep Kanwar, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Publication number: 20100311732Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).Type: ApplicationFiled: January 23, 2009Publication date: December 9, 2010Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Nishan Singh, Gurmeet Kaur Nanda, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Publication number: 20080114005Abstract: There are provided derivatives having PPAR agonist activity. The derivatives include compounds and/or their pharmaceutically acceptable salts; the compounds having the formula (I) wherein A has the structure (II) or (III); X is chosen from —CH2—, —O—, —NH—, and —S—; Y is chosen from —O—, —NH—, and —S—; Z, which may be located in any position of substitution, is hydrogen or halogen; R1 and R2, which may be the same or different, are independently chosen from hydrogen and C1-C8 alkyl, or R1 and R2 together form a carbocyclic ring having from 4 to 6 carbon atoms; R3 is chosen from hydrogen and C1-C8 alkyl; R4, R5, and R6, which may be the same or different, are independently chosen from hydrogen and C1-C8 alkyl; and n is 1 to 6. Various embodiments and variants are provided.Type: ApplicationFiled: September 6, 2005Publication date: May 15, 2008Applicants: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.Inventors: Saibal Kumar Das, Sunil Kumar Singh, Gurram Ranga Madhavan, Debnath Bhuniya, Javed Iqbal, Sudhir Kumar Sharma, Ranjan Chakrabarti